Can Awiqli Help Novo Nordisk Build a New Growth Engine Beyond GLP-1s?
Novo Nordisk NVO recently launched Awiqli (insulin icodec-abae) in the United States, introducing the first once-weekly basal insulin for…
Lilly’s long-acting insulin wins NICE blessing ahead of potential UK approval
For patients living with Type 2 diabetes in the United Kingdom, a more convenient treatment option may be…
Pursuing patient options, Novo kicks off trial testing smaller doses of Wegovy pill
Just eight months after it introduced its oral version of semaglutide for obesity, also known as the Wegovy…
Novo Nordisk commences study for reduced Wegovy pill dosing
Novo Nordisk has begun a late-stage clinical trial to evaluate whether lower doses of its oral pill, Wegovy,…
How Does LLY’s Q2 GLP-1 Portfolio Performance Stack Up Against NVO’s?
Eli Lilly LLY remains a dominant player in the GLP-1 market, led by Mounjaro for type II diabetes (T2D)…
Novo Nordisk (CPSE:NOVO B) Stock Still Looks Undervalued After Dutch Court Win
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St’s investing ideas for…
Novo Nordisk Launches 450-Person Trial to Find Lowest Effective Wegovy Pill Dose — BigGo Finance
Novo Nordisk (NVO) has initiated a late-stage clinical trial to determine whether lower doses of its oral Wegovy…
Can Eli Lilly Catch Novo Nordisk in the Oral GLP-1 Race?
The battle between Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO) has so far been defined by blockbuster injectable…
Pfizer’s Obesity Push: Can Berobenatide Take Market Share?
The global obesity market is emerging as one of the largest growth opportunities in pharmaceuticals. The market is…
Novo Nordisk (CPSE:NOVO B) Stock Still Looks Undervalued After Dutch Court Win
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St’s investing ideas for…
How Does LLY’s Q2 GLP-1 Portfolio Performance Stack Up Against NVO’s?
Eli Lilly LLY remains a dominant player in the GLP-1 market, led by Mounjaro for type II diabetes (T2D)…
Eli Lilly, Novo Nordisk and Merck: Buy, Sell or Hold?
Quick Read LLY dominates the GLP-1 race with 48% revenue growth and an unpriced Retratrutide catalyst, while NVO…